Coya Therapeutics investor reports 5.3% ownership stake
Coya Therapeutics, Inc. received an updated ownership report on its common stock from investor Orin Hirschman and affiliated entities on a Schedule 13G/A (Amendment No. 3).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Coya Therapeutics, Inc. received an updated ownership report on its common stock from investor Orin Hirschman and affiliated entities on a Schedule 13G/A (Amendment No. 3).
Mr. Hirschman reports beneficial ownership of 1,108,171 shares, representing 5.3% of Coya’s common stock, with sole voting and dispositive power over these shares. AIGH Capital Management LLC reports beneficial ownership of 975,404 shares, representing 4.7% of the class, also with sole voting and dispositive power. The filing is made on a passive basis, stating the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Coya Therapeutics.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does this Schedule 13G/A filing reveal about COYA ownership?
Who is the reporting person in the COYA Schedule 13G/A?
What stake in COYA does AIGH Capital Management LLC report?
Is the COYA Schedule 13G/A filing made on a passive basis?
What type of securities are covered in this COYA Schedule 13G/A?
When did the ownership event for this COYA Schedule 13G/A occur?
AI-generated analysis. How Rhea-AI works. Not financial advice.